Literature DB >> 26514880

Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

Felix Unverdorben1, Fabian Richter1, Meike Hutt1, Oliver Seifert1, Pauline Malinge2, Nicolas Fischer2, Roland E Kontermann1.   

Abstract

Fusion to an IgG Fc region is an established strategy to extend the half-life of therapeutic proteins. Most Fc fusion proteins, however, do not achieve the long half-life of IgGs. Based on findings that scFv-Fc fusion proteins exhibit a shorter half-life than the corresponding IgG molecules, we performed a comparative study of different antibody-derived Fc fusion proteins. We could confirm that fusion of single-chain Fv (scFv) and single-chain diabody (scDb) molecules to an Fc region yields in fusion proteins with substantially extended half-lives compared with the single-chain versions. However, even fusion proteins with a size similar to that of IgG, e.g., scDb-Fc, did not have a half-life as long as an IgG molecule. Binding to the neonatal Fc receptor (FcRn) under acidic and neutral conditions was similar for IgG and all Fc fusion proteins. However, we observed differences between IgG and the Fc fusion proteins for dissociation of FcRn-bound proteins induced by shifting from acidic to neutral pH, reflecting the physiological release mechanism, further supporting a contribution of the kinetics of pH-dependent release from FcRn to the pharmacokinetic properties of IgG and Fc fusion proteins.

Entities:  

Keywords:  Fc fusion protein; half-life; immunoglobulin G (IgG); neonatal Fc receptor (FcRn); pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 26514880      PMCID: PMC4966510          DOI: 10.1080/19420862.2015.1113360

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  31 in total

1.  Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.

Authors:  Giovanni Magistrelli; Pauline Malinge; Nadia Anceriz; Marjorie Desmurs; Sophie Venet; Sébastien Calloud; Bruno Daubeuf; Marie Kosco-Vilbois; Nicolas Fischer
Journal:  J Immunol Methods       Date:  2011-09-12       Impact factor: 2.303

2.  Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Authors:  Vania Kenanova; Tove Olafsen; Desiree M Crow; Gobalakrishnan Sundaresan; Murugesan Subbarayan; Nora H Carter; David N Ikle; Paul J Yazaki; Arion F Chatziioannou; Sanjiv S Gambhir; Lawrence E Williams; John E Shively; David Colcher; Andrew A Raubitschek; Anna M Wu
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

3.  Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.

Authors:  Dafne Müller; Anette Karle; Bettina Meissburger; Ines Höfig; Roland Stork; Roland E Kontermann
Journal:  J Biol Chem       Date:  2007-03-08       Impact factor: 5.157

Review 4.  Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

Authors:  Brian Gurbaxani; Miroslav Dostalek; Iain Gardner
Journal:  Mol Immunol       Date:  2013-08-02       Impact factor: 4.407

5.  Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis.

Authors:  Andreas Hombach; Claudia Heuser; Hinrich Abken
Journal:  Int J Cancer       Date:  2005-06-10       Impact factor: 7.396

6.  Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Authors:  Takuo Suzuki; Akiko Ishii-Watabe; Minoru Tada; Tetsu Kobayashi; Toshie Kanayasu-Toyoda; Toru Kawanishi; Teruhide Yamaguchi
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

7.  Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes.

Authors:  Tina Korn; Rolf Müller; Roland E Kontermann
Journal:  J Immunother       Date:  2004 Mar-Apr       Impact factor: 4.456

8.  Pharmacokinetics of engineered human monomeric and dimeric CH2 domains.

Authors:  Kurt Gehlsen; Rui Gong; Dave Bramhill; David Wiersma; Shaun Kirkpatrick; Yangping Wang; Yang Feng; Dimiter S Dimitrov
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

9.  A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.

Authors:  Colby A Souders; Stuart C Nelson; Yang Wang; Andrew R Crowley; Mark S Klempner; William Thomas
Journal:  MAbs       Date:  2015       Impact factor: 5.857

10.  Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.

Authors:  Angela Schoch; Hubert Kettenberger; Olaf Mundigl; Gerhard Winter; Julia Engert; Julia Heinrich; Thomas Emrich
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

View more
  26 in total

1.  A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice.

Authors:  Yuanyuan Kuang; Veronica Zorzi; Damiano Buratto; Gaia Ziraldo; Flavia Mazzarda; Chiara Peres; Chiara Nardin; Anna Maria Salvatore; Francesco Chiani; Ferdinando Scavizzi; Marcello Raspa; Min Qiang; Youjun Chu; Xiaojie Shi; Yu Li; Lili Liu; Yaru Shi; Francesco Zonta; Guang Yang; Richard A Lerner; Fabio Mammano
Journal:  EBioMedicine       Date:  2020-06-15       Impact factor: 8.143

2.  Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Authors:  Junpeng Qi; Xiuling Li; Haiyong Peng; Erika M Cook; Eman L Dadashian; Adrian Wiestner; HaJeung Park; Christoph Rader
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

3.  Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.

Authors:  Rebecca T van Dorsten; Bronwen E Lambson; Constantinos Kurt Wibmer; Marc S Weinberg; Penny L Moore; Lynn Morris
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

4.  Regulatory T Cells and Their Derived Cytokine, Interleukin-35, Reduce Pain in Experimental Autoimmune Encephalomyelitis.

Authors:  Samuel S Duffy; Brooke A Keating; Chamini J Perera; Justin G Lees; Ryan S Tonkin; Preet G S Makker; Pascal Carrive; Oleg Butovsky; Gila Moalem-Taylor
Journal:  J Neurosci       Date:  2019-01-16       Impact factor: 6.167

Review 5.  Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics.

Authors:  Mouldy Sioud
Journal:  Mol Biotechnol       Date:  2019-04       Impact factor: 2.695

6.  Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells.

Authors:  Yi-Chiu Kuo; Cheng-Fu Kuo; Kurt Jenkins; Alfur Fu-Hsin Hung; Wen-Chung Chang; Miso Park; Brenda Aguilar; Renate Starr; Jonathan Hibbard; Christine Brown; John C Williams
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

7.  The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse.

Authors:  Charles E Hay; Laura E Ewing; Michael D Hambuchen; Shannon M Zintner; Juliana C Small; Chris T Bolden; William E Fantegrossi; Paris Margaritis; S Michael Owens; Eric C Peterson
Journal:  J Pharmacol Exp Ther       Date:  2020-04-03       Impact factor: 4.030

8.  Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors.

Authors:  Jenny Ling-Yu Chen; Chun-Kai Pan; Yu-Sen Huang; Ching-Yi Tsai; Chun-Wei Wang; Yu-Li Lin; Sung-Hsin Kuo; Ming-Jium Shieh
Journal:  Cancer Immunol Immunother       Date:  2020-08-06       Impact factor: 6.968

9.  Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions.

Authors:  Luke F Pennington; Pascal Gasser; Daniel Brigger; Pascal Guntern; Alexander Eggel; Theodore S Jardetzky
Journal:  J Allergy Clin Immunol       Date:  2021-05-12       Impact factor: 14.290

Review 10.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.